A Study to Assess the Safety of Using Fibroblast Growth Factor-2 With Periodontal Surgery in Japan (Phase 3)

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

This study aims to investigate the safety in using Trafermin (recombinant human basic fibroblast growth factor) with periodontal surgery.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Kaken Pharmaceutical
• Treatments: Mitogens

Criteria

Inclusion Criteria:

• Vertical intrabony defect from radiographs at baseline

• Age of 20 years or older

Exclusion Criteria:

• Using an investigational drug within the past 24 months

• Coexisting malignant tumour or history of the same

• Coexisting diabetes (HbA1C 6.5% or more)

• Taking bisphosphonates

• Coexisting gingival overgrowth or history of the same